Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$106.09 USD

106.09
253,687

-2.00 (-1.85%)

Updated Jul 30, 2024 03:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.

Cardinal Health (CAH) to Extend Warehouse Footing With New Center

by Zacks Equity Research

Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.

BD's (BDX) Latest Product to Transform Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.

Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.

Accuray's (ARAY) New Tie-Up to Augment Treatment Planning

by Zacks Equity Research

Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.

Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.

Why Is Masimo (MASI) Up 6.9% Since Last Earnings Report?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

DexCom (DXCM) to Boost Diabetes Management With New Coverage

by Zacks Equity Research

DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.

    Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System

    by Zacks Equity Research

    Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.

    Here's Why Investors Should Retain Integra (IART) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.

    Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

    Here's Why Investors Should Retain Cerner (CERN) Stock Now

    by Zacks Equity Research

    Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

    Stryker's (SYK) Q Guidance System Receives FDA Approval

    by Zacks Equity Research

    Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.

    Thermo Fisher (TMO) North America Sales Grow, Margin Woe Stays

    by Zacks Equity Research

    Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.

    Is Masimo (MASI) a Solid Growth Stock? 3 Reasons to Think " Yes "

    by Zacks Equity Research

    Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    Reasons to Retain Integer Holdings (ITGR) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.

    Here's Why Investors Should Retain Illumina (ILMN) Stock Now

    by Zacks Equity Research

    Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.

    Here's Why You Should Retain PerkinElmer (PKI) Stock Now

    by Zacks Equity Research

    PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

    Tandem Diabetes (TNDM) Pump Shipment Recovers, Price Issue Ails

    by Zacks Equity Research

    Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.

    Integra (IART) Gains From Innovation Amid Cost Constraints

    by Zacks Equity Research

    Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.

    CVS Health (CVS) to Improve Primary Care With New Offering

    by Zacks Equity Research

    CVS Health (CVS) debuts the new CVS Health Virtual Primary Care solution to allow consumers to obtain care whenever necessary.

    NextGen Healthcare (NXGN) Unveils Health Data Hub Insights

    by Zacks Equity Research

    NextGen Healthcare's (NXGN) newly launched tool can help healthcare providers to receive a complete picture of the community and patient health.

    Here's Why You Should Retain Merit Medical (MMSI) Stock Now

    by Zacks Equity Research

    Investors continue to be optimistic about Merit Medical (MMSI) due to its strong product portfolio.